Currently, the most widely used criteria for assessing response to therapy in high-grade
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or …

Background The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in
all of oncology. Although advances have been made in the treatment of GBM, encouraging …

A recent joint meeting was held on January 30, 2014, with the US Food and Drug
Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, …

Purpose: We previously reported that autologous dendritic cells pulsed with acid-eluted tumor
peptides can stimulate T cell–mediated antitumor immune responses against brain tumors …

Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …

Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying
mechanisms are not understood. Single-cell analyses of patient-derived models and clinical …